These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
361 related articles for article (PubMed ID: 1645616)
21. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line. Yang JX; Luo Y; Qiu HM; Tang WX Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770 [TBL] [Abstract][Full Text] [Related]
22. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin. Lau DH; Lewis AD; Ehsan MN; Sikic BI Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140 [TBL] [Abstract][Full Text] [Related]
23. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance. Wang YY; Teicher BA; Shea TC; Holden SA; Rosbe KW; al-Achi A; Henner WD Cancer Res; 1989 Nov; 49(22):6185-92. PubMed ID: 2804968 [TBL] [Abstract][Full Text] [Related]
24. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair. Bungo M; Fujiwara Y; Kasahara K; Nakagawa K; Ohe Y; Sasaki Y; Irino S; Saijo N Cancer Res; 1990 May; 50(9):2549-53. PubMed ID: 2158392 [TBL] [Abstract][Full Text] [Related]
25. Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Moritaka T; Kiura K; Ueoka H; Tabata M; Segawa Y; Shibayama T; Takigawa N; Ohnoshi T; Harada M Anticancer Res; 1998; 18(2A):927-33. PubMed ID: 9615743 [TBL] [Abstract][Full Text] [Related]
26. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells. Stordal BK; Davey MW; Davey RA Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310 [TBL] [Abstract][Full Text] [Related]
27. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Behrens BC; Hamilton TC; Masuda H; Grotzinger KR; Whang-Peng J; Louie KG; Knutsen T; McKoy WM; Young RC; Ozols RF Cancer Res; 1987 Jan; 47(2):414-8. PubMed ID: 3539322 [TBL] [Abstract][Full Text] [Related]
28. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Tozawa K; Oshima T; Kobayashi T; Yamamoto N; Hayashi C; Matsumoto T; Miwa H Anticancer Res; 2008; 28(4B):2087-92. PubMed ID: 18751380 [TBL] [Abstract][Full Text] [Related]
29. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines. Aida T; Bodell WJ Cancer Res; 1987 Mar; 47(5):1361-6. PubMed ID: 3469016 [TBL] [Abstract][Full Text] [Related]
30. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629 [TBL] [Abstract][Full Text] [Related]
31. Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines. Mellish KJ; Kelland LR Cancer Res; 1994 Dec; 54(23):6194-200. PubMed ID: 7954466 [TBL] [Abstract][Full Text] [Related]
32. Glutathione related enzymes in cis-diamminedichloroplatinum (II)-sensitive and-resistant human ovarian carcinoma cells. Oguchi H; Kikkawa F; Kojima M; Maeda O; Mizuno K; Suganuma N; Kawai M; Tomoda Y Anticancer Res; 1994; 14(1A):193-200. PubMed ID: 7909418 [TBL] [Abstract][Full Text] [Related]
33. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Sharp SY; Rogers PM; Kelland LR Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070 [TBL] [Abstract][Full Text] [Related]
34. Modulation of cytotoxicity and cellular pharmacology of 1,2-diaminocyclohexane platinum (IV) complexes mediated by axial and equatorial ligands. Kido Y; Khokhar AR; al-Baker S; Siddik ZH Cancer Res; 1993 Oct; 53(19):4567-72. PubMed ID: 8402629 [TBL] [Abstract][Full Text] [Related]
35. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Goto S; Yoshida K; Morikawa T; Urata Y; Suzuki K; Kondo T Cancer Res; 1995 Oct; 55(19):4297-301. PubMed ID: 7671239 [TBL] [Abstract][Full Text] [Related]
36. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096 [TBL] [Abstract][Full Text] [Related]
37. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Kuppen PJ; Schuitemaker H; van 't Veer LJ; de Bruijn EA; van Oosterom AT; Schrier PI Cancer Res; 1988 Jun; 48(12):3355-9. PubMed ID: 2897238 [TBL] [Abstract][Full Text] [Related]
38. Increased expression of thioredoxin/adult T-cell leukemia-derived factor in cisplatin-resistant human cancer cell lines. Yamada M; Tomida A; Yoshikawa H; Taketani Y; Tsuruo T Clin Cancer Res; 1996 Feb; 2(2):427-32. PubMed ID: 9816187 [TBL] [Abstract][Full Text] [Related]
39. Characterization of a cisplatin-resistant subline of murine RIF-1 cells and reversal of drug resistance by hyperthermia. Mansouri A; Henle KJ; Benson AM; Moss AJ; Nagle WA Cancer Res; 1989 May; 49(10):2674-8. PubMed ID: 2713851 [TBL] [Abstract][Full Text] [Related]
40. Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells. Yang YY; Woo ES; Reese CE; Bahnson RR; Saijo N; Lazo JS Mol Pharmacol; 1994 Mar; 45(3):453-60. PubMed ID: 7511778 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]